• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc. (Amendment)

    2/14/23 4:00:28 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVS alert in real time by email
    SC 13G/A 1 c28230sc13ga2.htm AMENDMENT NO. 2

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Corvus Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

     

    221015100

    (CUSIP Number)

     

     

     

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ýRule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 8 
     

     

    CUSIP No. 221015100

     

    13G/A Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*

    (a)  ¨

    (b)  ý

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

    Number of

     Shares

     BENEFICIALLY
    Owned by

     Each Reporting
    Person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    pN

     

     Page 2 of 8 
     

     

    CUSIP No. 221015100

     

    13G/A Page 3 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL MANAGEMENT, LLC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a)  ¨

    (b)  ý

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

    Number of

     Shares

     BENEFICIALLY
    Owned by

     Each Reporting
    Person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    oo

     

     Page 3 of 8 
     

     

    CUSIP No. 221015100

     

    13G Page 4 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    KEVIN TANG

     

    2 Check the Appropriate Box if a Member of a Group*

    (a)  ¨

    (b)  ý

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    UNITED STATES

    Number of

     Shares

     BENEFICIALLY
    Owned by

     Each Reporting
    Person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    IN

     

     Page 4 of 8 
     

     

    Item 1(a).Name of Issuer:

     

    Corvus Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    863 Mitten Road, Suite 102, Burlingame, CA 94010

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 221015100

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management. 

     

     Page 5 of 8 
     

     

    The percentages used herein are based on 46,553,511 shares of Common Stock outstanding as of November 3, 2022, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on November 3, 2022.

     

    (b)Percent of Class:

     

    Tang Capital Partners 0.0%
    Tang Capital Management 0.0%
    Kevin Tang 0.0%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date:  February 14, 2023    
           
           
    TANG CAPITAL PARTNERS, LP  
           
    By: Tang Capital Management, LLC, its General Partner  
           
           
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
           
           
    TANG CAPITAL MANAGEMENT, LLC  
           
           
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
           
           
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8

     

     

    Get the next $CRVS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRVS

    DatePrice TargetRatingAnalyst
    1/2/2025$11.00Buy
    H.C. Wainwright
    8/18/2023$7.00Outperform
    Oppenheimer
    12/3/2021$5.00 → $8.00Overweight
    Cantor Fitzgerald
    12/1/2021$8.00Buy
    Jefferies
    8/3/2021$4.00 → $3.50Neutral
    Mizuho
    7/16/2021$9.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CRVS
    SEC Filings

    See more
    • Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

      6/13/25 4:02:09 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

      6/4/25 7:00:11 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.

      SCHEDULE 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      5/15/25 3:34:17 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jones William Benton bought $34,624 worth of shares (20,000 units at $1.73), increasing direct ownership by 15% to 153,773 units (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/7/24 5:06:34 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Miller Richard A Md bought $1,000,000 worth of shares (577,634 units at $1.73) (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/7/24 5:05:52 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Orbimed Advisors Llc exercised 1,397,684 in-the-money shares at a strike of $3.50 and sold $4,891,894 worth of shares (1,176,332 units at $4.16) (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      7/1/25 9:23:37 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thompson Peter A. exercised 1,397,684 in-the-money shares at a strike of $3.50 and sold $4,891,894 worth of shares (1,176,332 units at $4.16) (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      7/1/25 9:17:05 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Grais Linda

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      6/16/25 4:28:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

      SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China. Corvus co-founded Angel Pharma to develop its pipeline in greater China. Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize soquelit

      6/25/25 8:00:00 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

      SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is taking place June 11-14, 2025 in Barcelona. The poster will be presented by Gonçalo Boleto, M.D., MSc, a rheumatologist at Centro Académico de Medicina de Lisboa, Portugal. It was selected as a top 10 abstract by the Emerging EULAR Network (EMEUNET), a network of young rheumatologists and researchers in the

      6/11/25 7:00:00 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

      Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patient

      6/4/25 7:00:00 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Corvus Pharmaceuticals with a new price target

      H.C. Wainwright initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $11.00

      1/2/25 7:32:41 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Corvus Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Corvus Pharmaceuticals with a rating of Outperform and set a new price target of $7.00

      8/18/23 8:04:45 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on Corvus Pharmaceuticals with a new price target

      Cantor Fitzgerald reiterated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $8.00 from $5.00 previously

      12/3/21 9:11:26 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company's board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member. "We're thrilled to welcome Richard to our board," said Richard A. Miller, M.D., chairman, president and chief executive officer of Corvus. "Richard has a proven track record in the biotechnology sector and a deep understanding of the global pharmaceutic

      4/9/25 4:01:54 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

      BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara, who is a proven leader with more than 30 years of commercial experience in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio strategy, and new product planning. "Corvus is leading the development of ITK inhibition as a platform opportunity across oncology and immune diseases. The addition of Jeff as chief business officer strengthens our ability to maximize the potential of our ITK programs, both

      2/6/24 4:05:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

      BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediately. His initial focus will be to lead the development of CPI-818, the Company's ITK inhibitor, for the treatment of immune disorders such as T cell lymphomas, autoimmune and allergic diseases.  CPI-818 is currently being studied in a Phase 1/1b clinical trial for the treatment of T cell lymphomas, the results of which we believe could support advancing CPI-818 into a global Phase 2 trial. In addition, recent resea

      7/21/22 4:05:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc.

      SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      8/1/24 9:18:47 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      5/13/24 4:52:14 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Corvus Pharmaceuticals Inc.

      SC 13G - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      5/9/24 5:29:29 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Financials

    Live finance-specific insights

    See more
    • Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

      Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million Soquelitinib data to be highlighted on conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutica

      5/8/25 4:02:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

      Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate

      5/8/25 4:01:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

      Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the S

      4/23/25 4:08:12 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care